Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Autor: Andrew J Kwok, Eleanor Barnes, R Levin, Derrick W. Crook, D Crawford-Jones, Y Peng, E Perez, Marta Oliveira, Peto Tea., Nicole Stoesser, S Camara, K K Chau, Monique Andersson, Sally Beer, Matthew Catton, Y Warren, M Borak, L Blackwell, Tim James, Anita Justice, Abbie Bown, A Espinosa, Ashley Otter, Alex J. Richardson, M Emmenegger, Katie Jeffery, W Dejnirattsai, M Fernandez Mendoza, Julian C. Knight, A Linder, L Koukouflis, T Lockett, Rutger J. Ploeg, Tao Dong, Alison Howarth, J K Baillie, H P Tsang, Daniel Ebner, Gillian Rodger, L Silva-Reyes, Sarah Hoosdally, Timothy M Walker, Richard Vipond, S Fassih, Silvia D'Arcangelo, Alex Sienkiewicz, C Wilson, Aimee R. Taylor, Nicola A. Burgess-Brown, Sarah Oakley, Bassam Hallis, Alexander J. Mentzer, Tim Brooks, Cathy Rowe, L Martins Ferreira, Conor Feehily, Thomas G Ritter, S Marinou, N Gent, George Doherty, S Dimitriadis, Juthathip Mongkolsapaya, D Fox McKee, Christopher J. Groves, F Karpe, Kate E. Dingle, Prem Perumal, U Leuschner, Teresa L Street, P M Hammond, Carrow I. Wells, David W Eyre, James Kavanagh, Brian D. Marsden, Richard J. Cornall, Donal T. Skelly, J Pascoe, A Sobrino Diaz, Elizabeth A. Clutterbuck, V Gallardo Sanchez, Justine K. Rudkin, L Mason, R K Young, Susanna Dunachie, T Fordwoh, D S Kim, Dequaire Jmm., Mukhopadhyay Smm., B Horsington, Devender Roberts, E Y Jones, Kathryn Auckland, K Withycombe, Jennifer Hill, H Pickford, Christina Dold, Sheila F Lumley, Angela Sweed, Heli Harvala, A Beveridge, Rory Fairhead, K Paddon, Sadia Bibi, John Frater, Lisa Stockdale, J Morrow, David I. Stuart, Matt J. Neville, M K Verheul, T H Foord, Stuart Cox, Alejandra Fernández-Cid, Christine S. Rollier, L Stafford, Andrew J. Pollard, Susan Wareing, R Kirton, Jesse Coker, Malcolm G Semple, Paul Klenerman, A Mobbs, Thomas Christott, H Thraves, D Georgiou, Gavin R. Screaton, S Felle, José William Martínez, Philippa C Matthews, Stephanie B Hatch, Mark A. Ainsworth

Publikováno v: The Lancet Infectious Diseases
The Lancet. Infectious Diseases

Summary Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology is considered key to population-level surveillance an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d7b37124193c7e3af682cfab113650

Structural basis for inhibition of the lysosomal two-pore channel TPC2 by a small molecule antagonist.

Autor: Chi G; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK. Electronic address: gamma.chi@cmd.ox.ac.uk., Jaślan D; Walther-Straub-Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Ludwig-Maximilians-Universität, Nussbaumstrasse 26, 80336 Munich, Germany., Kudrina V; Walther-Straub-Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Ludwig-Maximilians-Universität, Nussbaumstrasse 26, 80336 Munich, Germany., Böck J; Walther-Straub-Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Ludwig-Maximilians-Universität, Nussbaumstrasse 26, 80336 Munich, Germany., Li H; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Pike ACW; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Rautenberg S; Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität, Butenandtstrasse 7, 81377 Munich, Germany., Krogsaeter E; Walther-Straub-Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Ludwig-Maximilians-Universität, Nussbaumstrasse 26, 80336 Munich, Germany., Bohstedt T; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Wang D; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., McKinley G; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Fernandez-Cid A; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Mukhopadhyay SMM; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Burgess-Brown NA; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK., Keller M; Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität, Butenandtstrasse 7, 81377 Munich, Germany., Bracher F; Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität, Butenandtstrasse 7, 81377 Munich, Germany., Grimm C; Walther-Straub-Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Ludwig-Maximilians-Universität, Nussbaumstrasse 26, 80336 Munich, Germany; Immunology, Infection and Pandemic Research IIP, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Munich/Frankfurt, Germany., Dürr KL; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Nuffield Department of Medicine Research Building, Oxford OX3 7FZ, UK.

Publikováno v: Structure (London, England : 1993) [Structure] 2024 Aug 08; Vol. 32 (8), pp. 1137-1149.e4. Date of Electronic Publication: 2024 May 29.

Cryo-EM structure of the human Kv3.1 channel reveals gating control by the cytoplasmic T1 domain.

Autor: Chi G; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK., Liang Q; Department of Neuroscience and Vickie and Jack Farber Institute for Neuroscience, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, 19107, UK., Sridhar A; Department of Applied Physics, Science for Life Laboratory, KTH, Solna, Sweden., Cowgill JB; Department of Applied Physics, Science for Life Laboratory, KTH, Solna, Sweden., Sader K; Materials and Structural Analysis, Thermo Fisher Scientific, Achtseweg Noord 5, 5651 GG, Eindhoven, Netherlands., Radjainia M; Materials and Structural Analysis, Thermo Fisher Scientific, Achtseweg Noord 5, 5651 GG, Eindhoven, Netherlands., Qian P; Materials and Structural Analysis, Thermo Fisher Scientific, Achtseweg Noord 5, 5651 GG, Eindhoven, Netherlands., Castro-Hartmann P; Materials and Structural Analysis, Thermo Fisher Scientific, Achtseweg Noord 5, 5651 GG, Eindhoven, Netherlands., Venkaya S; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Exscientia Ltd., The Schrödinger Building, Heatley Road, The Oxford Science Park, Oxford, OX4 4GE, UK., Singh NK; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK., McKinley G; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK., Fernandez-Cid A; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Exact Sciences Ltd., The Sherard Building, Edmund Halley Road, The Oxford Science Park, Oxford, OX4 4DQ, UK., Mukhopadhyay SMM; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Exscientia Ltd., The Schrödinger Building, Heatley Road, The Oxford Science Park, Oxford, OX4 4GE, UK., Burgess-Brown NA; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.; Exact Sciences Ltd., The Sherard Building, Edmund Halley Road, The Oxford Science Park, Oxford, OX4 4DQ, UK., Delemotte L; Department of Applied Physics, Science for Life Laboratory, KTH, Solna, Sweden., Covarrubias M; Department of Neuroscience and Vickie and Jack Farber Institute for Neuroscience, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, 19107, UK., Dürr KL; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK. katharina.duerr@omass.com.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK. katharina.duerr@omass.com.; OMass Therapeutics, Ltd., The Schrödinger Building, Heatley Road, The Oxford Science Park, Oxford, OX4 4GE, UK. katharina.duerr@omass.com.

Publikováno v: Nature communications [Nat Commun] 2022 Jul 15; Vol. 13 (1), pp. 4087. Date of Electronic Publication: 2022 Jul 15.

Identification, mapping and relative quantitation of SARS-CoV-2 Spike glycopeptides by Mass-Retention Time Fingerprinting.

Autor: Chalk R; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK. rod.chalk@cmd.ox.ac.uk., Greenland WEP; Agilent Technologies, Lakeside, Cheadle Royal Business Park, Cheadle, Cheshire, UK., Moreira T; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Coker J; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Mukhopadhyay SMM; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Williams E; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Manning C; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Bohstedt T; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., McCrorie R; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Fernandez-Cid A; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK., Burgess-Brown NA; Centre for Medicines Discovery, ORCRB, University of Oxford, Oxford, UK.

Publikováno v: Communications biology [Commun Biol] 2021 Aug 03; Vol. 4 (1), pp. 934. Date of Electronic Publication: 2021 Aug 03.

The structural basis of fatty acid elongation by the ELOVL elongases.

Autor: Nie L; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; CRELUX GmbH, Planegg-Martinsried, Germany., Pascoa TC; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Pike ACW; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Bushell SR; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Orbit Discovery, Oxford, UK., Quigley A; Membrane Protein Laboratory, Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK., Ruda GF; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Evotec Ltd, Milton, Abingdon, UK., Chu A; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Department of Biochemistry, Oxford University, Oxford, UK., Cole V; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Genomics Centre, South African Medical Research Council, Cape Town, South Africa., Speedman D; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Moreira T; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Shrestha L; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Mukhopadhyay SMM; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Burgess-Brown NA; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Love JD; Albert Einstein College of Medicine, Department of Biochemistry, Bronx, NY, USA.; Novo Nordisk A/S, Måløv, Denmark., Brennan PE; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Alzheimer's Research UK Oxford Drug Discovery Institute, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Carpenter EP; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK. liz.carpenter@cmd.ox.ac.uk.; Vertex Pharmaceuticals Ltd, Milton, Abingdon, UK. liz.carpenter@cmd.ox.ac.uk.

Publikováno v: Nature structural & molecular biology [Nat Struct Mol Biol] 2021 Jun; Vol. 28 (6), pp. 512-520. Date of Electronic Publication: 2021 Jun 10.